Company news
NurExone Biologic Inc news in 2026
NurExone Biologic Inc's news releases, calls and decks from 2026, newest first.
NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
October 30, 2026
NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
October 22, 2026
NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
October 9, 2026
NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
September 18, 2026
NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
September 16, 2026
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
September 14, 2026
NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
August 31, 2026
NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
August 28, 2026
NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
August 21, 2026
NurExone Announces Closing of C$1,066,078 Private Placement
August 20, 2026
NurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
August 14, 2026
NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
August 12, 2026
NurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
July 30, 2026
Corporate Updates – NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
Corporate Updates - NurExone appoints Mr. David Stolick to the Board of Directors
July 28, 2026
NurExone Announces Closing of Non-Brokered Private Placement
June 30, 2026
Exo-Top, NurExone's wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico
June 24, 2026
NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
June 1, 2026
NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
May 19, 2026
NurExone Advances to Stage 2 of EU-Backed EIT Health Catapult Programme 2026
May 14, 2026
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
April 27, 2026
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
April 16, 2026
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026
April 10, 2026
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization
April 7, 2026
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy
April 1, 2026
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement
March 26, 2026
NurExone Announces Corporate Updates
March 11, 2026
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
February 27, 2026
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production
February 10, 2026
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise
January 30, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 18 slides · September 2026
- Investor Presentation (May 2026)
Investor deck · 17 slides · May 2026